Evercore ISI Group analyst Vijay Kumar has maintained an Outperform rating on Revvity while raising the price target for the stock. The new target of $125 represents an increase from the previous level of $110.

Rating and Price Target Details

The revision reflects a positive outlook on the company's performance. The following table summarizes the updated analyst action:

Revvity is listed on the NYSE under the ticker symbol RVTY.

Bernstein has reinstated its coverage on Revvity with a Market Perform rating and established a price target of $115. Analyst Eve Burstein issued the rating, providing a valuation benchmark for the company's shares listed on the NYSE under the ticker RVTY. The reinstatement follows a period where the stock was likely not covered by the firm, signaling a renewed focus on the company's performance.

The Market Perform rating suggests that Bernstein expects Revvity's stock to perform in line with the broader market or its sector peers. The $115 price target offers investors a specific reference point for the stock's potential upside or downside over the firm's investment horizon. This assessment is based on the analyst's evaluation of the company's current financial health, market position, and future growth prospects.

Revvity operates in the life sciences and diagnostics sectors, providing products and services that enable customers in the pharmaceutical, biotechnology, and clinical laboratory markets. The company's performance is often tied to research and development spending trends and the demand for diagnostic testing. Bernstein's reinstatement indicates that the firm sees sufficient clarity in Revvity's business outlook to provide guidance to investors.

Investors will likely monitor Revvity's progress towards the $115 target, looking for updates on product launches, regulatory approvals, and market expansion strategies. The rating and target serve as key inputs for portfolio decisions, particularly for those tracking the healthcare and technology segments of the market.